Jaume Mora, MD, PhD: Naxitamab Approval for High-Risk Neuroblastoma in the Bone or Bone Marrow

Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scientific Director of Oncology and Hematology at Sant Joan de Déu Barcelona Children's Hospital and lead investigator of one of the trials on which the approval was based, speaks with i3 Health about the benefits of naxitamab for patients with relapsed/r...
Continue reading

Lurbinectedin Approved: Metastatic Small-Cell Lung Cancer

The FDA has granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer (SCLC) experiencing disease progression on or after platinum-based chemotherapy. The efficacy of lurbinectedin, a selective inhibitor of oncogenic transcription, was investigated in a multinational, single-arm, open-label phase 2 basket trial, PM1183-B-005-14 (Study B-005; NCT02454972), which enrolled adults with SCLC previously treated with only one chemothe...
Continue reading

In High-Risk Neuroblastoma, Tandem Transplant Is Superior

A randomized clinical trial reports that in patients with neuroblastoma, tandem autologous stem cell transplant improves outcomes compared with single transplant. Neuroblastoma, a malignancy of the developing sympathetic nervous system, is responsible for around 10% to 12% of childhood cancer deaths. For the 43% of patients who present with high-risk disease, which involves either widespread metastasis in patients over the age of 18 months and/or amplification of the MYCN oncogene, the standard ...
Continue reading

Knowledge Gaps in the Treatment of Carcinoid Syndrome

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symptoms of carcinoid syndrome can negatively impact patients' quality of life and functioning. Baseline data collected from a continuing nursing education (CNE)-approved Oncology Nursing Strategy Session titled Optimizing Management of Carcinoid Syndrom...
Continue reading

JMJD6 Identified as a Neuroblastoma Tumorigenic Factor

Researchers have identified the JMJD6 gene as a critical factor for neuroblastoma tumorigenesis, indicating potential for a new targeted drug therapy treatment strategy. The most prevalent solid tumor in early childhood cancers, neuroblastoma comprises 15% of total childhood cancer deaths. Neuroblastoma is distinctive from adult cancers in that it is characterized by frequent chromosome copy number variations, and its most prominent features are gene deletion, amplification, or gain. While chrom...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.